University of Nottingham

Researchers at the University of Nottingham developed a regenerative material using a patient's own blood and self-assembling peptides, mimicking the body's natural healing processes for personalized therapies.

UK research finds workers feel overwhelmed by digital technology and constant connectivity, leading to 'techno-strain.' Hyperconnectivity, with texting and emails, makes it hard to detach from work, blurring work-home boundaries. The study calls for measures to protect digital workers' well-being.

Graft Polymer (UK) Plc announces a binding letter of agreement to acquire Awakn Life Sciences Corp., issuing 2,074,378,592 new shares valued at £4.98 million. The acquisition is subject to due diligence, regulatory approvals, and shareholder consent, aiming to strengthen Graft Polymer's position in mental health therapeutics.

UKRI invests in projects to safeguard Christmas dinner staples from climate change, including alternative proteins, bioengineered potatoes, reduced antibiotic use in animals, and energy-efficient cooking. Initiatives span from alternative proteins to sustainable wine production, aiming to ensure future food security and sustainability.

New research from the University of Nottingham finds that repeated paracetamol doses in people aged 65+ increase risks of gastrointestinal, cardiovascular, and renal complications. The study, published in Arthritis Care and Research, suggests careful consideration of paracetamol use for chronic pain in older adults due to its minimal pain-relief effect and potential harm.

A study by the University of Nottingham found that long-term use of strong anticholinergic drugs, prescribed for conditions like bladder issues, Parkinson’s, and depression, significantly increases dementia risk in patients aged 55 and over. The research, published in JAMA Internal Medicine, showed a nearly 50% increased risk of dementia among those who used these medications daily for three years or more. The study also highlighted the need for careful consideration of anticholinergic drug risks and regular medication reviews, particularly for middle-aged individuals.

Diabetes medication GLP-1 receptor agonists (GLP-1 RAs) show promise in reducing alcohol consumption, particularly in obese individuals, by targeting the brain's reward center. Further research is needed to explore this potential treatment for excessive alcohol use.

Researchers at the University of Nottingham developed a 'biocooperative' approach using blood-based materials for personalized regenerative therapies, mimicking natural healing processes and potentially enabling 3D-printed implants.

A British study suggests GLP-1 diabetes medications like Ozempic may reduce alcohol consumption, especially in obese heavy drinkers, by targeting the brain's reward center. The study reviewed data from six prior studies, finding that GLP-1 meds were associated with reduced alcohol use and related health issues.